MONCYTE Health Raises EUR 1 Million Seed Capital to Advance Personalized Treatment for High Cholesterol
HELSINKI, Finland (October 8th, 2024) – MONCYTE Health diagnostics, developing proprietary technology to optimize treatment and prevention of cardiovascular disease, has closed a EUR 1 million seed round to fund its go-to-market strategy. Its technology is designed to help clinicians select more effective personalized treatments for patients with high cholesterol. The round was led by Finnish venture capital investors Inventure, Almaral, and Athensmed and included funding from University of Helsinki Funds, private European investors, and a grant from Business Finland.
